Table 1.
Multivariate Survival Analysis of miR-124 Expression, Sex, Age, Stage, Grade of Differentiation, and Histological Type in Relationship to Overall Survival in Colorectal Cancer Patients Who Received FOLFOX (fluorouracil+oxaliplatin) or XELOX (capecitabine+oxaliplatin) Therapy
| Variable | Unfavorable/Favorable | HR | 95% CI | p Value |
|---|---|---|---|---|
| miR-124 expression | downregulated/upregulated | 2.279 | 1.468–3.538 | <0.001 |
| Sex | male/female | 0.884 | 0.575–1.361 | 0.576 |
| Age | >66/≤66 years | 1.880 | 1.228–2.880 | 0.004 |
| Stage | III/II | 2.394 | 1.495–3.833 | <0.001 |
| Differentiation | poor/moderate+well | 1.290 | 0.857-1.942 | 0.223 |
| Histological type | mucinous/nonmucinous | 0.855 | 0.495–1.475 | 0.573 |
HR, hazard ratio; CI, confidence interval.